Therapy of mild to moderate luminal Crohn's disease.

Détails

ID Serval
serval:BIB_A4C81014B08E
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Institution
Titre
Therapy of mild to moderate luminal Crohn's disease.
Périodique
Digestion
Auteur⸱e⸱s
Michetti P., Juillerat P., Mottet C., Gonvers J.J., Burnand B., Vader J.P., Froehlich F., Felley C.
ISSN
0012-2823
Statut éditorial
Publié
Date de publication
2005
Peer-reviewed
Oui
Volume
71
Numéro
1
Pages
13-8
Langue
anglais
Notes
Publication types: Journal Article ; Review - Publication Status: ppublish
Résumé
The management of luminal Crohn's disease, the most common form of initial presentation of the disease, depends on the location and the severity of the lesions. Mild to moderate disease represents a relatively large proportion of patients with a first flare of luminal disease, which may also be associated with perianal disease. As quality of life of these patients correlates with disease activity, adequate therapy is a central goal of the overall patient management. Treatment options include mainly sulfasalazine, budesonide and systemic steroids, while the role of mesalazine and antibiotics remains controversial. The role of biological therapies in mild to moderate disease has not been thoroughly evaluated and will not be discussed here.
Mots-clé
Anti-Infective Agents, Crohn Disease, Drug Administration Schedule, Drug Therapy, Combination, Glucocorticoids, Humans, Severity of Illness Index, Treatment Outcome
Pubmed
Web of science
Création de la notice
25/01/2008 15:58
Dernière modification de la notice
20/08/2019 15:10
Données d'usage